Jarlier V, Nicolas M H, Fournier G, Philippon A
Service de Bactérologie, Faculté de Médecine, Pitié-Salpêtrière, France.
Rev Infect Dis. 1988 Jul-Aug;10(4):867-78. doi: 10.1093/clinids/10.4.867.
Before 1985 at the Pitié-Salpêtrière Hospital in Paris (2,400 beds), resistance to cefotaxime in clinical isolates of Enterobacteriaceae involved only species producing inducible class 1 beta-lactamase. Between November 1985 and April 1987, however, 62 isolates (57 of Klebsiella pneumoniae and five of Escherichia coli) showed decreased susceptibility to cefotaxime (mean MIC, 8-16 micrograms/mL). The transferability of cefotaxime resistance in E. coli K12 was demonstrated for 15 of 16 selected isolates. By isoelectric focusing using iodometric detection with 20 mg of ceftriaxone/100 mL and determination of substrate and inhibition profiles, three beta-lactamases mediating cefotaxime resistance were identified as SHV-2 (isoelectric point [pI] 7.6), CTX-1 (pI 6.3), and "SHV-2-type" or SHV-3 (pI 6.98). The three beta-lactamases hydrolyzed penicillins and cephalosporins (including cefotaxime and ceftriaxone) and were therefore designated "extended broad-spectrum beta-lactamases" (EBS-Bla). The enzymes conferred to derivatives a high level of resistance to amoxicillin, ticarcillin, piperacillin, and cephalothin and a decreased degree of susceptibility (i.e., MICs increased by 10- to 800-fold) to cefotaxime, ceftriaxone, ceftazidime, and aztreonam. These beta-lactamases did not affect the activity of cephamycins (cefoxitin, cefotetan, moxalactam) or imipenem. Synergy between clavulanate or sulbactam (2 micrograms/mL) and amoxicillin was greater against derivatives producing EBS-Bla than against those producing TEM-1, TEM-2, or SHV-1; this synergy was greater with clavulanate than with sulbactam against derivatives producing SHV-2 and the SHV-2-type enzyme but was similar with clavulanate and sulbactam against those producing CTX-1. A double-disk synergy test performed with cefotaxime and Augmentin disks (placed 30 mm apart, center to center) seemed a useful and specific test for the detection of strains producing EBS-Bla.
1985年以前,在巴黎皮蒂 - 萨尔佩特里埃医院(拥有2400张床位),肠杆菌科临床分离株对头孢噻肟的耐药性仅涉及产生诱导性1类β-内酰胺酶的菌种。然而,在1985年11月至1987年4月期间,62株分离株(57株肺炎克雷伯菌和5株大肠杆菌)对头孢噻肟的敏感性降低(平均MIC为8 - 16微克/毫升)。在16株选定的大肠杆菌K12分离株中,有15株证明了头孢噻肟耐药性的可转移性。通过使用20毫克头孢曲松/100毫升进行碘量检测的等电聚焦以及底物和抑制谱的测定,鉴定出三种介导头孢噻肟耐药性的β-内酰胺酶为SHV-2(等电点[pI]7.6)、CTX-1(pI 6.3)和“SHV-2型”或SHV-3(pI 6.98)。这三种β-内酰胺酶可水解青霉素和头孢菌素(包括头孢噻肟和头孢曲松),因此被指定为“超广谱β-内酰胺酶”(EBS-Bla)。这些酶使衍生物对阿莫西林、替卡西林、哌拉西林和头孢噻吩具有高水平的耐药性,而对头孢噻肟、头孢曲松、头孢他啶和氨曲南的敏感性降低(即MIC增加10至800倍)。这些β-内酰胺酶不影响头霉素(头孢西丁、头孢替坦、莫西沙星)或亚胺培南的活性。棒酸或舒巴坦(2微克/毫升)与阿莫西林之间的协同作用,对产生EBS-Bla的衍生物比对产生TEM-1、TEM-2或SHV-1的衍生物更强;对于产生SHV-2和SHV-2型酶的衍生物,棒酸的这种协同作用比舒巴坦更强,但对于产生CTX-1的衍生物,棒酸和舒巴坦的协同作用相似。用头孢噻肟和奥格门汀纸片(中心距30毫米)进行的双纸片协同试验似乎是检测产生EBS-Bla菌株的一种有用且特异的试验。